## Bicyclic Melanocortin-Specific Comp unds

## ABSTRACT OF THE DISCLOSURE

5 Melanocortin receptor-specific bicyclic compounds having the structure:

$$(I) \qquad \begin{array}{c} R_2 \\ X \\ N \\ Z \end{array} \qquad \begin{array}{c} R_1 \\ \end{array}$$

and stereoisomer and pharmaceutically acceptable salts thereof, where R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> X and z are as

described in the specification, which are agonists, antagonists or mixed agonists and antagonists at
one or more melanocortin receptors, and having utility in the treatment of melanocortin receptorrelated disorders and conditions. Pharmaceutical compositions containing a compound of structure
(I) and methods relating to the use thereof are also disclosed.